Related Experiment Video

Updated: Aug 7, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Combinatorial biomarkers: From early toxicology assays to patient population profiling

Ronald Koop1

  • 1MelTec, Leipziger Strasse 44, D-39120 Magdeburg, Germany. ronald.koop@meltec.de

Drug Discovery Today
|June 1, 2005
PubMed

Insights

Advanced biomarkers are crucial for predicting and monitoring diseases and toxicology, reducing drug development failures. Combinatorial biomarkers, coupled with high content screening, enhance decision-making by providing vital functional biology insights.

Area of Science:

  • Biomarker Discovery
  • Drug Development
  • Systems Biology

Background:

  • High clinical failure rates necessitate advanced biomarkers for predicting and monitoring disease and toxicology.
  • Current biomarker applications include screening drug candidates for toxicity and identifying patient populations.
  • Combinatorial biomarkers represent a step towards a systems biology approach in drug development.

Purpose of the Study:

  • To highlight the need for advanced biomarkers in drug development.
  • To emphasize the role of combinatorial biomarkers in improving prediction and monitoring.
  • To showcase the integration of combinatorial biomarkers with high content screening for enhanced decision-making.

Main Methods:

  • Utilizing combinatorial biomarkers.
  • Implementing high content screening.
  • Employing novel, high content in situ proteomic technology.

Main Results:

  • Combinatorial biomarkers provide crucial information on functional biology.
  • The integration of biomarkers and high content screening supports knowledge-based decision-making.
  • Advanced biomarkers improve the prediction and monitoring of disease and toxicology mechanisms.

Conclusions:

  • Combinatorial biomarkers are essential for reducing clinical failure rates in drug development.
  • High content in situ proteomic technology combined with combinatorial biomarkers offers significant advantages.
  • This approach enhances the understanding of functional biology and supports informed decisions in drug development.

More Related Videos

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans09:01

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

Published on: March 14, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...